|本期目录/Table of Contents|

[1]郭伟华.艾迪注射液与TCF 联合对胃癌患者化疗反应及生存质量的影响[J].慢性病学杂志,2016,(07):743-745.
　GUO Wei-hua.Effects of Addie injection and TCF combined chemotherapy on response to chemotherapy and quality of life of patients with gastric cancer[J].,2016,(07):743-745.
点击复制

艾迪注射液与TCF 联合对胃癌患者化疗反应及生存质量的影响(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2016年07期
页码:
743-745
栏目:
论著
出版日期:
2016-08-27

文章信息/Info

Title:
Effects of Addie injection and TCF combined chemotherapy on response to chemotherapy and quality of life of patients with gastric cancer
作者:
郭伟华
新乡市中心医院肿瘤内三科，河南新乡453000
Author(s):
GUO Wei-hua
No. 3 Department of Internal Medicine - Oncology, Central Hospital of Xinxiang City, Xinxiang, Henan 453000, China Corresponding author: GUO Wei-hua, E-mail: 2658200988@qq.com
关键词:
胃癌; 艾迪注射液; 联合化疗
Keywords:
Gastric cancer;  Addie injection;  Combined chemotherapy
分类号:
R735.2
DOI:
-
摘要:
目的探讨艾迪注射液与TCF 化疗联合干预对胃癌患者化疗反应及生存质量的影响。方法纳入胃癌患 者76 例，随机分为观察组和对照组各38 例，观察组给予TCF 方案即艾迪注射液联合紫杉醇（TAX） +亚叶酸钙 (CF） +5-氟尿嘧啶（5-Fu） 治疗，对照组给予单纯TCF 化疗干预，治疗周期均为4周。检测两组胃癌患者不同 治疗方案临床疗效以及治疗后不良反应发生情况，并采用EORT-CQLQ-C30 评分量表评估两组生存质量包括 躯体功能、角色功能、认知功能、情绪功能和社会功能5 个功能。结果观察组、对照组总有效率分别为 81.58%、60.52%，差异有统计学意义（P＜0.05）。观察组不良反应发生率为7.89%，显著低于对照组的26.32% （P＜0.05）。治疗前两组生存质量各项评分比较差异无统计学意义（P＞0.05）；观察组治疗后躯体功能、角色功 能、认知功能、情绪功能和社会功能评分分别为（89.55± 11.11）、（70.88± 13.66）、（74.54± 11.20）、（70.99± 13.02）、（70.98±14.96） 分，均显著高于对照组（P＜0.05）。结论艾迪注射液与TCF 化疗联合干预治疗胃癌 患者临床疗效显著，艾迪注射液能显著降低毒性，安全性高，并能有效提高患者生存质量。
Abstract:
Objective To explore the effects of Addie injection and TCF combined chemotherapy on response to chemotherapy and quality of life of patients with gastric cancer. Methods A total of 76 patients with gastric cancer were randomly divided into the observation group and the control group, 38 cases in each group. The observation group were treated with Addie injection combined with taxol (TAX), calcium folinate (CF) and 5- fluorouracil (5- Fu), while the control group were treated with TCF chemotherapy alone. The clinical curative effects of different treatment regimens in two groups and occurrence of adverse reactions after treatment were observed. The quality of life of the two groups, including physical function, role function, cognitive function, emotional function and social function were analyzed. Results The total effective rates in the observation group and the control group were 81.58% and 60.52% respectively and the difference was significant (P<0.05). The incidence of adverse reactions in the observation group (7.89% ) was significantly lower than that in the control group (26.32% ) (P < 0.05). There was no significant difference in the 5 quality of life between the two groups before treatment (P＞0.05). After treatment, scores of the 5 quality of life indexes in the observation group [(89.55± 11.11), (70.88± 13.66), (74.54±11.20), (7.099±13.02), (70.98±14.96)] were significantly higher than those in the control group (all P<0.05). Conclusions Combined chemotherapy of Aidi injection and TCF has significant clinical curativeeffect in the treatment of patients with gastric cancer. Aidi injection can significantly reduce toxicity, has high safety and improve the quality of life of patients.

参考文献/References:

[1] 丁艳,王丽丽. 胃肠癌根治手术后患者期间生存质量的调查分析 [J].护理学报,2010,17(11B):12-14.
[2] 雷素扬,郭领.胃癌患者术后生活质量调查及影响因素分析[J].中 国实用护理杂志,2012,28(12):9-11.
[3] 任玲. 化疗联合同步放疗治疗胃癌对患者生活质量的影响分析 [J].中国医学创新,2015,12(3):66-68.
[4] 郁有贵,杨秀芳,陈梅,等.改良DCF 方案治疗晚期胃癌33 例临 床观察[J].中国临床新医学,2014,7(12):1132-1133.
[5] 周战英. 艾迪注射液联合替吉奥治疗晚期胃癌的临床疗效观察 [J].临床医学,2014,34(12):126,144.
[6] 习隽丽,彭波习.中药方联合TCF 方案化疗改善中晚期胃癌患者 的疗效评价[J].世界华人消化杂志,2014,22(36):5684-5687.
[7] 葛云亮.艾迪注射液联合MF/CF 方案化疗晚期胃癌临床观察[J]. 中国民族民间医药,2010,2(10):31-32.
[8] 刘继禹,石岩,张宗江. 艾迪注射液的临床应用[J]. 疾病监测与控 制,2010,4(2):73-75.
[9] 李然,宁华. 艾迪注射液联合化疗治疗胃癌疗效和安全性的系统 评价[J].中国药房,2011,22(40):3813-3817.

备注/Memo

备注/Memo:
作者简介：郭伟华，硕士，主治医师，研究方向：恶性肿瘤的内科治疗 通信作者：郭伟华，E-mail: 2658200988@qq.com
更新日期/Last Update: 2016-08-27